Endoscopic injections of Teflon to treat urinary incontinence in women
Various forms of treatment have been developed to cure urinary stress incontinence in women. All surgical procedures aim to increase the urethral resistance to urine outflow and eventually to restore a normal angle between the proximal urethra and the bladder neck.' Politano proposed using perineal injections of Teflon to treat incontinence in men after transurethral resection of the prostate and extended the technique to women.2 3 Heer injected Teflon into the wall of the urethra to increase its length and closing pressure.4 For the past three years we have used an endoscopic technique for giving injections of Teflon to women suffering from incontinence.
Patients, methods, and results
We treated 56 women aged (mean 59) suffering from urinary stress incontinence. Twelve patients presented with cystoceles, four of whom had had an operation for this; 19 had undergone hysterectomy; four had undergone perineal amputation; and eight had had several operations to treat incontinence by classic vesicosuspension using sling procedures. Follow up ranged from three to 25 (mean 12) months.
An 8 French gauge polyethylene catheter ending in a needle was guided through the shaft of a regular cystoscope. The needle was inserted deep into the urethral wall, about 1 cm below the bladder neck. Teflon was injected using a small syringe with a metallic sheet and piston (Storz). About 3 ml was injected at 1500, 1800, and 2100 (total around 10 ml). A bladder catheter was used for 24 hours afterwards, and patients stayed in hospital for about three days. Oral 
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Teflon paste is a suspension of fine polymer particles in glycerine and polysorbate. It has been used for years in surgery and otolaryngology and is an inert material that produces minimal inflammation. 5 We initially used this technique only in patients who had had several previous operations without success. As the results were encouraging we used it for all patients eligible for classic operations. We noted minor complications such as occasional retention and bladder discomfort. Although no abscess developed, we prescribed broad spectrum antibiotics for two weeks.
Our main fear was of inducing obstruction of the bladder outlet, but measurement of urine flow after injection of Teflon showed an average decrease in rate of only 5 ml/s, whereas a urethral pressure profile showed an appreciable increase in the functional length of the urethra. This technique has obvious advantages: hospital stay is shortened, obesity or previous surgical procedures do not prevent injection, and it does not hinder later open surgery. In June 1981 she began to feel increasingly tired. In November she had intermittent left ptosis and diplopia, variable weakness of neck flexors and triceps, with no bulbar or other weakness. Reflexes and sensation were intact. Edrophonium testing and tests for antiacetylcholine receptor and antinuclear antibodies gave positive results. Electromyography, plain chest radiography, and immunoglobulins IgA and IgG showed nothing abnormal. IgM concentration was 0-4 g/l (normal 0 6-3-0). Her HLA state was Al, A2, B12, DR2, DR4. Penicillamine induced myasthenia gravis was diagnosed and penicillamine stopped. After two months she had only occasional ptosis and after five months (May 1982) no myasthenic symptoms.
Her arthritis deteriorated, so fenclofenac 600 mg twice daily was prescribed in March 1982. After two weeks a rash developed which resolved on withdrawing fenclofenac, recurring when she was rechallenged. Her myasthenia did not recur. In July 1982 she began sodium aurothiomalate 10 mg weekly, increasing by 10 mg a week for five weeks, when she developed a rash. Simultaneously her ptosis and diplopia reappeared. She required prednisolone (initially 10 mg daily) for the rash, the dosage reducing over five months, and pyridostigmine (initially 60 mg four times a day) for four months. Her myasthenia had resolved after six months.
No previous reports have described recurrence of penicillamine induced myasthenia when gold has been subsequently given. Our patient's myasthenia had virtually disappeared when she suffered a toxic reaction to fenclofenac, but this did not provoke recurrence of her myasthenia. Thus it is unlikely that the return of symptoms with gold was due to a non-specific upset. Since gold alone has never been reported to cause myasthenia, it probably aggravated a penicillamine induced defect.
The mechanism of action of penicillamine is not clear, but it affects the immune system and has induced several autoimmune disorders. It may directly stimulate oligoclonal B cell activity, upset the balance between T helper and suppressor cells, or alter antigens by hapten formation. The sulphydryl group of penicillamine reduces disulphide bonds in several proteins. Acetylcholine receptor subunits also contain vulnerable disulphide bonds. Penicillamine binds,' probably via these sulphydryl links, to subunits of electric fish acetylcholine receptor, reducing their affinity for acetylcholine. This may directly affect neuromuscular transmission, as in guinea pigs, where penicillamine reduces the amplitude of miniature end plate potentials. One possibly analogous case in man has been described, in which a patient noted weakness within 24 hours of beginning penicillamine, improving immediately when the drug was stopped.2 Equally this binding suggests a mechanism for antigenic alteration of acetylcholine receptor and loss of tolerance.
Carbocysteine is structurally similar to penicillamine, and people with a low capacity for producing sulphoxides of carbocysteine may be similarly unable to metabolise penicillamine. Poor sulphoxidisers of carbocysteine are more likely to develop proteinuria or thrombocytopenia when taking penicillamine.3 Our patient was a very poor sulphoxidiser (index 52). Possibly this inability to metabolise the sulphydryl group makes interaction with acetylcholine receptor more likely.
Penicillamine toxicity, especially proteinuria or marrow suppression, may be more likely in patients who have had a toxic reaction to gold.4 The order of treatment with gold and penicillamine probably makes no difference to recurrence of toxicity. 5 Caution should be exercised in prescribing gold to a patient who has developed penicillamine induced myasthenia.
Normal energy intake in undernourished patients with Crohn's disease Malnutrition is common in Crohn's disease and an important cause is widely believed to be reduced food intake as a consequence of anorexia or fear of abdominal pain. Scientific data, however, are remarkably few. We have investigated the energy intakes of a group of chronically malnourished outpatients with Crohn's disease and compared the results with those in a group of well nourished outpatients with ulcerative colitis and a group of healthy subjects.
Patients, methods, and results
We studied 26 patients (17 men) with Crohn's disease and 22 (12 men) with ulcerative colitis. All were ambulant and attending a gastrointestinal clinic, and their mean ages (1 SD) were 36 (14) and 43 (14) years, respectively.
Mean duration of disease was 10 years in the patients with Crohn's disease and eight years in those with ulcerative colitis. We also studied 22 healthy subjects (13 men), whose mean age (1 SD) was 34 (15) 
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These results show that malnourished outpatients with Crohn's disease have similar energy intakes to those of well nourished outpatients with ulcerative colitis and healthy subjects. Undernutrition might therefore be accounted for by malabsorption, inflammation, and enteric loss of nutrients, and possibly the increased metabolic demands of the disease cannot be compensated for by an apparently normal energy intake. In undernourished ambulatory patients with Crohn's disease increasing the energy intake by enteral supplementation may result in an increase in weight and other nutritional variables.4 Similarly parenteral hyperalimentation in acute severe Crohn's disease may improve nutrition and contribute to primary management.5 These observations support the concept that undernourished patients with Crohn's disease may have a "relative energy deficiency."
Our study suggests that a reduced food intake is not a common feature in chronically undernourished patients with Crohn's disease; nevertheless, this does not in any way obviate the important role of nutritional care in their management.
